Clinical Trial

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

Name: Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma — clinical trial record (NCT06574698)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.

Trial Details

NCT Number	NCT06574698
Lead Sponsor	Guangzhou Women and Children's Medical Center
Conditions	Neuroblastoma, GD2 Antibody (Naxitamab)
Enrollment	64 participants
Start Date	2024-05-06
Primary Completion	2029-12-31 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-28